SFG
ALXN

SevenBridge Financial Group’s Alexion Pharmaceuticals ALXN Stock Holding History

SevenBridge Financial Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-542
Closed -$71K – 625
2019
Q2 		$71K Sell
542
-215
-28% -$27.7K 0.03% 238
2019
Q1 		$102K Buy
+757
New +$94.1K 0.04% 178

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

SevenBridge Financial Group's ALXN Position: Q3 2019 in Review

SevenBridge Financial Group sold out of Alexion Pharmaceuticals (ALXN) in Q3 2019, closing a stake of 542 shares — an estimated $71K sold.

SevenBridge Financial Group first reported a position in ALXN in Q1 2019 and held it in 2 quarters. The position peaked at $102K in Q1 2019. 648 funds tracked by Wall St. Rank hold ALXN as of Q3 2019.

  • SevenBridge Financial Group reported no remaining Alexion Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • SevenBridge Financial Group sold 542 Alexion Pharmaceuticals shares in Q3 2019, an estimated $71K.
  • SevenBridge Financial Group first reported a position in Alexion Pharmaceuticals in Q1 2019 and held it in 2 quarters.
  • SevenBridge Financial Group's Alexion Pharmaceuticals position peaked at $102K in Q1 2019.
  • 648 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2019.

Based on SevenBridge Financial Group's 13F filing for Q3 2019, filed 9 Oct 2019.